Literature DB >> 11002227

Visual estimate of the percentage of carcinoma is an independent predictor of prostate carcinoma recurrence after radical prostatectomy.

G F Carvalhal1, P A Humphrey, P Thorson, Y Yan, C G Ramos, W J Catalona.   

Abstract

BACKGROUND: The importance of tumor size measurements as predictors of disease recurrence after radical prostatectomy in patients with prostate carcinoma remains somewhat controversial, and many pathologists do not report these measurements routinely. The authors studied the correlation between the visual estimate of the percentage of carcinoma in prostatic tissue from radical prostatectomy specimens and prostate carcinoma recurrence rates in a series of 595 patients who underwent radical prostatectomy.
METHODS: A total of 595 men with clinically localized prostate carcinoma were treated by the same surgeon (W.J.C.) from 1993 through 1997. The percentage of carcinoma in radical prostatectomy specimens from these patients was assessed microscopically through visual estimate. The authors used Kaplan-Meier product limit estimates, log-rank statistics, and the Cox proportional hazards model to evaluate the percentage of carcinoma in the pathologic specimens as predictors of recurrence free survival.
RESULTS: Of the 595 patients, 46 (8%) had evidence of tumor recurrence. The mean percentage of carcinoma in the prostatectomy specimen was 11.3% in the group of patients who did not have disease recurrence and 23.8% in the group of patients who did experience disease recurrence. The percentage of carcinoma, preoperative prostate specific antigen levels, tumor differentiation (histologic Gleason grade), and pathologic stage all were significant predictors of disease recurrence according to the Kaplan-Meier method (all log-rank P values < 0.0001). Using the Cox proportional hazards model, controlling for all of these variables, only pathologic tumor stage, Gleason score, and percentage of carcinoma proved to be independent predictors of disease recurrence. In the final model, which included pathologic stage, Gleason score, and percentage of carcinoma, for each 5% increase in the percentage of carcinoma in the surgical specimen, there was an 11% incremental increase in the chance of tumor recurrence.
CONCLUSIONS: The visual estimate of the percentage of carcinoma in prostatic tissue specimens from patients who undergo radical prostatectomy is a practical, simple, and inexpensive method that provides important prognostic information after radical prostatectomy. Copyright 2000 American Cancer Society.

Entities:  

Mesh:

Year:  2000        PMID: 11002227     DOI: 10.1002/1097-0142(20000915)89:6<1308::aid-cncr16>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  13 in total

1.  The prognostic significance of percentage of tumour involvement according to disease risk group in men treated with radical prostatectomy.

Authors:  Jong Jin Oh; Sang Cheol Lee; Chang Wook Jeong; Cheol Yong Yoon; Seong Jin Jeong; Sung Kyu Hong; Seok-Soo Byun; Yoon Kwan Rho; Gheeyoung Choe; Sang Eun Lee
Journal:  Asian J Androl       Date:  2011-09-26       Impact factor: 3.285

2.  Maximum tumor diameter adjusted to the risk profile predicts biochemical recurrence after radical prostatectomy.

Authors:  Georg Müller; Malte Rieken; Gernot Bonkat; Joel Roman Gsponer; Tatjana Vlajnic; Christian Wetterauer; Thomas C Gasser; Stephen F Wyler; Alexander Bachmann; Lukas Bubendorf
Journal:  Virchows Arch       Date:  2014-08-17       Impact factor: 4.064

3.  In Organ-confined Prostate Cancer, Tumor Quantitation Not Found to Aid in Prediction of Biochemical Recurrence.

Authors:  Yujiro Ito; Emily A Vertosick; Daniel D Sjoberg; Andrew J Vickers; Hikmat A Al-Ahmadie; Ying-Bei Chen; Anuradha Gopalan; Sahussapont J Sirintrapun; Satish K Tickoo; James A Eastham; Peter T Scardino; Victor E Reuter; Samson W Fine
Journal:  Am J Surg Pathol       Date:  2019-08       Impact factor: 6.394

4.  The association between tumour density and prostate cancer recurrence following radical prostatectomy.

Authors:  Luke T Lavallée; Rodney H Breau; Mark A Preston; Gayanna Raju; Christopher Morash; Steve Doucette; Ronald G Gerridzen; James Eastham; Ilias Cagiannos
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

5.  Prostate cancer with bladder neck involvement: pathologic findings with application of a new practical method for tumor extent evaluation and recurrence-free survival after radical prostatectomy.

Authors:  Athanase Billis; Leandro L L Freitas; Luis A Magna; Adil B Samara; Ubirajara Ferreira
Journal:  Int Urol Nephrol       Date:  2004       Impact factor: 2.370

6.  Correlation between serum prostate-specific antigen and cancer volume in prostate glands of different sizes.

Authors:  Gustavo F Carvalhal; Saima N Daudi; Donghui Kan; Dana Mondo; Kimberly A Roehl; Stacy Loeb; William J Catalona
Journal:  Urology       Date:  2010-09-16       Impact factor: 2.649

7.  Tumor extent in radical prostatectomy specimens: is it an independent prognostic factor for biochemical (PSA) progression following surgery?

Authors:  Athanase Billis; Luciana Meirelles; Leandro L Freitas; Luis A Magna; Ubirajara Ferreira; Leonardo O Reis
Journal:  Int Urol Nephrol       Date:  2010-08-10       Impact factor: 2.370

8.  Tumor volume, tumor percentage involvement, or prostate volume: which is predictive of prostate-specific antigen recurrence?

Authors:  Matthew A Uhlman; Leon Sun; Danielle A Stackhouse; Arthur A Caire; Thomas J Polascik; Cary N Robertson; John Madden; Robin Vollmer; David M Albala; Judd W Moul
Journal:  Urology       Date:  2009-10-12       Impact factor: 2.649

9.  Comparison of prostate cancer volume measured by HistoScanning™ and final histopathological results.

Authors:  J Schiffmann; J Fischer; P Tennstedt; B Beyer; K Böhm; U Michl; M Graefen; G Salomon
Journal:  World J Urol       Date:  2013-11-24       Impact factor: 4.226

10.  Pretreatment tumor volume estimation based on total serum psa in patients with localized prostate cancer.

Authors:  Raphael Barroso Kato; Victor Srougi; Fernanda Aburesi Salvadori; Pedro Paulo Marino Rodrigues Ayres; Katia Moreira Leite; Miguel Srougi
Journal:  Clinics (Sao Paulo)       Date:  2008-12       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.